Literature DB >> 12217344

Comparable virus inactivation by bovine or vegetable derived Tween 80 during solvent/detergent treatment.

Holger Seitz1, Johannes Blümel, Ivo Schmidt, Hannelore Willkommen, Johannes Löwer.   

Abstract

A mixture of Tri-n-butyl phosphate (TNBP) and Polysorbate 80 (Tween 80) is often used for virus inactivation during the manufacture of medicinal products derived from human plasma. This procedure, known as solvent/detergent treatment, is of high effectiveness for inactivation of enveloped viruses. Tween 80 can be manufactured from bovine tallow or from vegetable material. As the bovine-derived Tween 80 is normally used for the solvent/detergent treatment, the question has been raised whether vegetable-derived Tween 80 can be applied as an alternative substance for the solvent/detergent treatment. Comparable inactivation studies were therefore performed using Vesicular Stomatitis Virus (VSV), Pseudorabiesvirus (PRV), Semliki Forest Virus (SFV) and Bovine Diarrhoea Virus (BVDV). In principle, no differences were observed in the effectiveness of the solvent/detergent treatment when bovine or vegetable-derived Tween 80 was used. The comparability in the efficiency of both detergents for virus inactivation was shown to be independent of solvent/detergent concentration, of temperature (16 degrees C and 6 degrees C vs. 27 degrees C and 25 degrees C) and protein concentration (10% and 5% human albumin). In summary, vegetable-derived Tween 80 is of the same effectiveness as bovine-derived Tween 80, when used for virus inactivation by the solvent/detergent treatment. Copyright 2002 The International Association for Biologicals. Published by Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12217344     DOI: 10.1006/biol.2002.0328

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  3 in total

1.  Maturation of the Gag core decreases the stability of retroviral lipid membranes.

Authors:  Candice Davidoff; Riley J Payne; Sharon H Willis; Benjamin J Doranz; Joseph B Rucker
Journal:  Virology       Date:  2012-09-17       Impact factor: 3.616

2.  Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products.

Authors:  Constanze Yue; Sebastian Teitz; Tomoyuki Miyabashi; Klaus Boller; Lia Laura Lewis-Ximenez; Sally A Baylis; Johannes Blümel
Journal:  Viruses       Date:  2019-03-07       Impact factor: 5.048

3.  Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.

Authors:  Herbert O Dichtelmüller; Lothar Biesert; Fabrizio Fabbrizzi; Rodrigo Gajardo; Albrecht Gröner; Ilka von Hoegen; Juan I Jorquera; Christoph Kempf; Thomas R Kreil; Dominique Pifat; Wendy Osheroff; Gerhard Poelsler
Journal:  Transfusion       Date:  2009-05-20       Impact factor: 3.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.